Current Lab Members
Rim Daher
Research Staff
Rim Daher holds a Master’s degree in Molecular Biology and Genetics from the University of Alberta. Her graduate research focused on post-fertilization pathways in C. elegans, where she used CRISPR-based genome editing and confocal microscopy to identify and characterize novel components of the MEMI pathway.
Her research training has provided her with a strong background in molecular genetics, genome editing, molecular biology, and advanced microscopy. She has also been actively involved in teaching and mentoring and has received multiple recognitions for her academic and teaching excellence, including two Graduate Student Teaching Awards.
In the Mirzaei Lab, Rim applies her expertise in molecular and cellular biology, CRISPR technologies, and microscopy to investigate tumor biology and tumor–immune interactions. Her work contributes to the lab’s efforts to understand the molecular mechanisms that regulate cancer progression and therapeutic response.
Elizabeth Reid
MSc Student
Elizabeth Reid is a graduate student pursuing her Master’s degree in Cancer Sciences at the University of Alberta. She previously earned her Bachelor’s degree in Honours Biochemistry from the University of Victoria, where she developed a strong interest in understanding the complex interactions between cancer and the immune system.
Her academic training has provided her with a strong foundation in biochemistry, molecular biology, and cancer biology. Through her graduate studies, Elizabeth is expanding her expertise in tumor biology and tumor–immune interactions while developing the experimental and analytical skills needed to investigate mechanisms underlying cancer progression and therapeutic response.
In the Mirzaei Lab, Elizabeth contributes to research aimed at understanding how cancer cells interact with the immune microenvironment. She is particularly interested in expanding her expertise in cancer biology and contributing to collaborative research that can advance our understanding of cancer and ultimately inform the development of improved therapeutic strategies.
Kaviya Devaraja
PhD Student
Kaviya Devaraja is a PhD student in the Mirzaei Lab at the University of Alberta. She previously earned her MSc from the Institute of Medical Science at the University of Toronto, where her research in Dr. Gelareh Zadeh’s laboratory focused on understanding the role of ICAM1 in glioblastoma-associated macrophages and the hypoxic tumor microenvironment. Her previous research experience also includes clinical and translational oncology studies at Princess Margaret Cancer Centre and The Hospital for Sick Children. Her academic and research background has provided her with expertise in glioblastoma biology, tumor–immune interactions, and cancer research.
In the Mirzaei Lab, Kaviya investigates the mechanisms underlying resistance of glioblastoma stem cells (GSCs) to chimeric antigen receptor (CAR) T-cell immunotherapy. Her research focuses on identifying tumor-intrinsic factors that enable GSCs to evade CAR T-cell-mediated killing and understanding how different GSC cellular states influence therapeutic response. Through this work, she aims to identify potential therapeutic targets and strategies to overcome immunotherapy resistance in glioblastoma.
Erica Zhang
MSc Student
Erica Zhang is a Master’s student at the University of Alberta. She previously completed her undergraduate studies in the Honors Immunology and Infection program, where her research focused on understanding how colorectal cancer influences macrophage function, particularly phagocytosis and antigen presentation. Her undergraduate research provided her with a foundation in immunology, cancer biology, and tumor–immune interactions.
In the Mirzaei Lab, Erica investigates how different molecular subtypes of colorectal cancer respond to immunotherapy. Her research focuses on identifying tumor-intrinsic mechanisms that influence antitumor immune responses and contribute to therapeutic resistance. Through her graduate studies, she aims to advance our understanding of the biological factors underlying differences in immunotherapy response across colorectal cancer subtypes.